MENU

APLS Stock Apellis Pharmaceuticals (APLS, $27.69) RSI Indicator left the oversold zone on January 14, 2025

A.I.dvisor
at Tickeron.com
Loading...
APLS - Apellis Pharmaceuticals
RSI signal
Bullish Trend
Odds of UP Trend
Tickeron
RSI signal
Price: $27.69
Daily change: -$0.9 (-3.15%)
Daily volume: 1.7M
Capitalization: $3.4B
Industry: Biotechnology
This is a signal that APLS's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options. A.I.dvisor looked back and found 23 similar cases where APLS's RSI Indicator left the oversold zone, and in of them led to a successful outcome. Odds of Success:

APLS in +3.50% Uptrend, growing for three consecutive days on January 07, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where APLS advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for APLS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

APLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on APLS as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

APLS moved below its 50-day moving average on January 10, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where APLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for APLS entered a downward trend on January 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. APLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.699) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). APLS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (5.152) is also within normal values, averaging (263.573).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutics and drug delivery technologies to address chronic inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Distributors
Address
100 Fifth Avenue
Phone
+1 617 977-5700
Employees
706
Web
https://www.apellis.com